FY2026 EPS Estimates for Pfizer Lifted by Leerink Partnrs

Pfizer Inc. (NYSE:PFE) – Equities research analysts at Leerink Partnrs upped their FY2026 EPS estimates for shares of Pfizer in a research report issued on Wednesday, April 30th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $3.25 per share for the year, up from their prior estimate of $3.14. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Leerink Partnrs also issued estimates for Pfizer’s FY2027 earnings at $3.24 EPS.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same quarter in the previous year, the business earned $0.82 EPS. Pfizer’s revenue was down 7.8% compared to the same quarter last year.

A number of other equities research analysts have also recently commented on the company. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price for the company. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Stock Performance

Shares of PFE opened at $24.19 on Friday. Pfizer has a 12 month low of $20.92 and a 12 month high of $31.54. The stock has a fifty day moving average price of $24.34 and a 200-day moving average price of $25.75. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $137.19 billion, a PE ratio of 17.16, a P/E/G ratio of 0.64 and a beta of 0.67.

Institutional Investors Weigh In On Pfizer

A number of institutional investors have recently added to or reduced their stakes in PFE. Nordea Investment Management AB boosted its position in Pfizer by 36.1% during the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock worth $108,002,000 after acquiring an additional 1,080,822 shares during the last quarter. Parsons Capital Management Inc. RI boosted its position in shares of Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock valued at $7,820,000 after acquiring an additional 159,984 shares during the last quarter. Mcdonald Partners LLC grew its holdings in shares of Pfizer by 9.9% in the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company’s stock valued at $2,926,000 after purchasing an additional 9,963 shares during the period. Merit Financial Group LLC raised its stake in Pfizer by 60.8% during the fourth quarter. Merit Financial Group LLC now owns 127,967 shares of the biopharmaceutical company’s stock worth $3,395,000 after purchasing an additional 48,397 shares during the period. Finally, Pensionfund Sabic boosted its holdings in Pfizer by 41.7% in the 4th quarter. Pensionfund Sabic now owns 85,000 shares of the biopharmaceutical company’s stock valued at $2,255,000 after purchasing an additional 25,000 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.11%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.